The Effect of Diltiazem on Tacrolimus Exposure: Model-Informed Precision Dosing in Kidney Transplant Patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20260611005

Enrollment

350

Registered

2026-06-11

Start date

2026-06-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney transplant patients diltiazem, pharmacokinetics, tacrolimus

Interventions

Kidney transplant patients receiving tacrolimus

Experimental Drug

Tacrolimus

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients aged 18 years or older 2. Patients who underwent kidney transplantation and received tacrolimus as standard CNI therapy

Exclusion criteria

Exclusion criteria: 1. Patients who did not receive tacrolimus during the follow-up period of the study 2. Patients who were switched to other tacrolimus products during the follow-up period 3. Patients who wee lost to follow-up and had no data available for the study

Design outcomes

Primary

Measure	Time frame
Factors affecting tacrolimus pharmacokinetics Within 1 year after transplantation Population pharmacokinetics	—

Secondary

Measure	Time frame
Proposed tacrolimus dosing Within 1 year after transplantation Population pharmacokinetics	—

Countries

Thailand

Contacts

Public ContactSayamon Sukkha

Mahidol University

sayamon.suk@mahidol.ac.th026448694

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026